LFSC - ETF AI Analysis
Top Page
F/M Emerald Life Sciences Innovation ETF (LFSC)
Rating:52Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year and in recent months, showing solid momentum.
Top Holdings Showing Strong Gains
Several of the largest positions, such as Spyre Therapeutics and Corcept Therapeutics, have posted strong advances, helping drive the fund’s returns.
Focused Exposure to Health Care Innovation
With most assets in health care and life sciences companies, the fund offers targeted exposure to a sector that can benefit from medical and biotech innovation.
Negative Factors
High Sector Concentration
The ETF is heavily concentrated in health care, so a downturn in this single sector could significantly hurt performance.
Limited Geographic Diversification
Almost all holdings are in U.S. companies, which reduces the benefits of global diversification and ties results closely to the U.S. market.
Above-Average Expense Ratio
The fund’s expense ratio is relatively high for an ETF, which means more of the returns are used to cover fees instead of going to investors.
LFSC vs. SPDR S&P 500 ETF (SPY)
AUM125.52M
RegionNorth America
Expense Ratio0.54%
Beta1.07
IssuerF/m
Inception DateOct 30, 2024
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,982
30 Day Avg. Volume4,598
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
63.52Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering38
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
LFSC Summary
LFSC is the F/M Emerald Life Sciences Innovation ETF, focused on innovative health care companies in pharma, biotech, and life sciences rather than tracking a traditional index. It mainly holds U.S. firms working on new drugs, medical tests, and treatments, including names like Guardant Health and United Therapeutics. Investors might consider LFSC if they want growth potential from cutting-edge medical breakthroughs and added diversification within the health care sector. However, this ETF is heavily concentrated in smaller, specialized biotech and pharma stocks, so its price can be very volatile and may go up and down sharply.
How much will it cost me?The F/M Emerald Life Sciences Innovation ETF (LFSC) has an expense ratio of 0.54%, meaning you’ll pay $5.40 per year for every $1,000 invested. This is slightly higher than average because it’s actively managed, focusing on specialized companies in the Pharma, Biotech & Life Sciences sector to capture unique growth opportunities.
What would affect this ETF?The LFSC ETF, focused on U.S.-based pharmaceutical, biotech, and life sciences companies, could benefit from advancements in medical technology, increased healthcare spending, and favorable regulatory approvals for new treatments. However, it may face challenges from rising interest rates, which can impact funding for innovation, and regulatory hurdles that could delay drug approvals or increase costs for its top holdings. Economic downturns or reduced government healthcare budgets could also negatively affect the sector.
LFSC Top 10 Holdings
LFSC is a pure play on U.S. life sciences, with performance largely steered by a handful of volatile biotech names. Travere Therapeutics and Corcept Therapeutics have been rising steadily, acting as key engines for the fund’s recent gains. Guardant Health adds another bright spot with improving momentum. On the flip side, Spyre Therapeutics and Cogent Biosciences have been lagging, their ongoing losses and bearish trends dragging on returns. Overall, this ETF is heavily concentrated in innovative but high-risk health care names, making it more of a roller coaster than a smooth ride.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Travere Therapeutics | 8.95% | $11.20M | $6.24B | 181.93% | 56 Neutral | |
| Corcept Therapeutics | 6.88% | $8.61M | $12.19B | 54.78% | 76 Outperform | |
| Spyre Therapeutics | 6.71% | $8.40M | $7.99B | 478.91% | 43 Neutral | |
| LivaNova | 6.53% | $8.18M | $4.31B | 39.06% | 63 Neutral | |
| Cogent Biosciences | 6.36% | $7.97M | $5.80B | 163.90% | 37 Underperform | |
| Mirum Pharmaceuticals | 4.47% | $5.60M | $6.38B | 32.18% | 56 Neutral | |
| BillionToOne, Inc. Class A | 4.23% | $5.29M | $4.66B | ― | ― | |
| Guardant Health | 3.85% | $4.82M | $21.12B | 186.69% | 61 Neutral | |
| Cytokinetics | 3.66% | $4.58M | $10.26B | 44.28% | 57 Neutral | |
| Axsome Therapeutics | 3.27% | $4.10M | $11.56B | 86.41% | 57 Neutral |
LFSC Technical Analysis
Neutral
―
Price Trends
46.29
Negative
43.12
Positive
39.71
Positive
Market Momentum
-0.27
Positive
43.04
Neutral
22.55
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For LFSC, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 46.47, equal to the 50-day MA of 46.29, and equal to the 200-day MA of 39.71, indicating a neutral trend. The MACD of -0.27 indicates Positive momentum. The RSI at 43.04 is Neutral, neither overbought nor oversold. The STOCH value of 22.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LFSC.
LFSC Peer Comparison
Comparison Results
Performance Comparison
LFSC
F/M Emerald Life Sciences Innovation ETF
45.37
17.57
63.20%
SAMT
Strategas Macro Thematic Opportunities ETF
―
―
―
GTOP
Goldman Sachs Technology Opportunities ETF
―
―
―
FEPI
REX FANG & Innovation Equity Premium Income ETF
―
―
―
IETC
iShares Evolved US Technology ETF
―
―
―
PINK
Simplify Health Care ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents